title: [Prevention of post-operative recurrence in Crohn's disease: a critical review of randomized controlled trials and meta-analyses of different therapeutic strategies].
abstract: Surgery is an almost inevitable event in Crohn's disease but is not curative; post-operative recurrence follows a sequential and predictable course. Prevention of post-operative recurrence in Crohn's disease is therefore a relevant problem in the management of the disease. Several drugs have been evaluated to decrease the risk of recurrence: these include mesalazine, antibiotics, probiotics, budesonide, thiopurines and biologic agents. This review focuses on the randomised controlled trials and meta-analyses addressing different drugs and strategies for preventing post-operative recurrence in Crohn's disease.
authors.affiliation: Unità Operativa Complessa Gastroenterologia ed Epatologia, Azienda Ospedaliera San Filippo Neri, Roma. g.margagnoni@libero.it
authors.forename: Giovanna
authors.initials: G
authors.lastname: Margagnoni
authors.forename: Valeria
authors.initials: V
authors.lastname: Clemente
authors.forename: Annalisa
authors.initials: A
authors.lastname: Aratari
authors.forename: Federica
authors.initials: F
authors.lastname: Fascì Spurio
authors.forename: Angela Maria
authors.initials: AM
authors.lastname: De Gregorio
authors.forename: Annalisa
authors.initials: A
authors.lastname: Spagnolo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Koch
authors.forename: Claudio
authors.initials: C
authors.lastname: Papi
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery; D004359:Drug Therapy, Combination; D016145:Endoscopy, Digestive System; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D016753:Interleukin-10 / Q000627:therapeutic use; D007778:Lactobacillus; D019804:Mesalamine / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D019936:Probiotics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D016753:Interleukin-10; D019804:Mesalamine; D019819:Budesonide; D000069285:Infliximab